Matthias G Von Herrath

Summary

Affiliation: La Jolla Institute for Allergy and Immunology
Country: USA

Publications

  1. pmc Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3
    Alusha A Mamchak
    Entelos Inc, Foster City, California, USA
    Diabetes 61:1490-9. 2012
  2. pmc Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNgamma
    G Fousteri
    Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    Diabetologia 53:1958-70. 2010
  3. ncbi request reprint Protection from type 1 diabetes in the face of high levels of activated autoaggressive lymphocytes in a viral transgenic mouse model crossed to the SV129 strain
    M G von Herrath
    Immunology and Neuropharmacology, The Scripps Research Institute, La Jolla, California 92121, USA
    Diabetes 50:2700-8. 2001
  4. pmc Can we learn from viruses how to prevent type 1 diabetes?: the role of viral infections in the pathogenesis of type 1 diabetes and the development of novel combination therapies
    Matthias von Herrath
    Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA
    Diabetes 58:2-11. 2009
  5. ncbi request reprint Vaccination to prevent type 1 diabetes
    Matthias G Von Herrath
    La Jolla Institute for Allergy and Immunology, Division of Immune Regulation, San Diego, CA 92121, USA
    Expert Rev Vaccines 1:25-8. 2002
  6. ncbi request reprint Introducing baselines for therapeutic use of regulatory T cells and cytokines in autoimmunity
    Matthias von Herrath
    La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121 1118, USA
    Trends Immunol 24:540-5. 2003
  7. ncbi request reprint Microorganisms and autoimmunity: making the barren field fertile?
    Matthias G Von Herrath
    Division of Developmental Immunology, Immune Regulation Laboratory, La Jolla Institute for Allergy and Immunology, 10355 Science Centre Drive, San Diego, California 92121, USA
    Nat Rev Microbiol 1:151-7. 2003
  8. ncbi request reprint Type 1 diabetes as a relapsing-remitting disease?
    Matthias von Herrath
    La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, California 92037, USA
    Nat Rev Immunol 7:988-94. 2007
  9. ncbi request reprint New trends in immunosuppression--sixth international congress. New drug candidates. 5-8 February 2004, Salzburg, Austria
    Matthias von Herrath
    Department of Neuropharmacology, Division of Virology IMM6, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    IDrugs 7:211-4. 2004
  10. doi request reprint Animal models of human type 1 diabetes
    Matthias von Herrath
    Center for Type 1 Diabetes Research, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA
    Nat Immunol 10:129-32. 2009

Research Grants

  1. DNA Vaccination & Regulatory Cells in Type I Diabetes
    Matthias von Herrath; Fiscal Year: 2003
  2. Role of a Non-Tolerant Autoantigen in Autoimmunity
    Matthias von Herrath; Fiscal Year: 2007
  3. Animal Models in Type 1 Diabetes and Multiple Sclerosis
    Matthias von Herrath; Fiscal Year: 2006
  4. Achieving Therapeutic Antigent-Specific Tolerance in Type 1 Diabetes
    Matthias von Herrath; Fiscal Year: 2007
  5. CXCR3 Chemokines in Type I Diabetes
    Matthias von Herrath; Fiscal Year: 2009
  6. How IL-10R blockade can resolve persistent viral infections
    Matthias G Von Herrath; Fiscal Year: 2010
  7. Role of a Non-Tolerant Autoantigen in Autoimmunity
    Matthias von Herrath; Fiscal Year: 2006
  8. Role of a Non-Tolerant Autoantigen in Autoimmunity
    Matthias von Herrath; Fiscal Year: 2003
  9. IMMUNE TOLERANCE INDUCTION BY APOPTOTIC BODIES
    Matthias von Herrath; Fiscal Year: 2005
  10. How Does blockade of CD40/CD40L Prevent Autoimmunity?
    Matthias von Herrath; Fiscal Year: 2005

Detail Information

Publications97

  1. pmc Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3
    Alusha A Mamchak
    Entelos Inc, Foster City, California, USA
    Diabetes 61:1490-9. 2012
    ....
  2. pmc Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNgamma
    G Fousteri
    Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    Diabetologia 53:1958-70. 2010
    ..Here we analysed the effect of B:9-23/IFA immunisation at later stages of the disease and the underlying mechanisms...
  3. ncbi request reprint Protection from type 1 diabetes in the face of high levels of activated autoaggressive lymphocytes in a viral transgenic mouse model crossed to the SV129 strain
    M G von Herrath
    Immunology and Neuropharmacology, The Scripps Research Institute, La Jolla, California 92121, USA
    Diabetes 50:2700-8. 2001
    ..This finding has important implications for interpreting numbers and pathogenicity of autoreactive lymphocytes in prediabetic patients of genetically diverse backgrounds...
  4. pmc Can we learn from viruses how to prevent type 1 diabetes?: the role of viral infections in the pathogenesis of type 1 diabetes and the development of novel combination therapies
    Matthias von Herrath
    Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA
    Diabetes 58:2-11. 2009
    ..In combination, these two immune elements have the potential to permanently stop type 1 diabetes. It is my belief that only combination therapies will enable the permanent prevention and curing of type 1 diabetes...
  5. ncbi request reprint Vaccination to prevent type 1 diabetes
    Matthias G Von Herrath
    La Jolla Institute for Allergy and Immunology, Division of Immune Regulation, San Diego, CA 92121, USA
    Expert Rev Vaccines 1:25-8. 2002
    ..Both will be discussed in this chapter and suitable combinatorial approaches will be suggested...
  6. ncbi request reprint Introducing baselines for therapeutic use of regulatory T cells and cytokines in autoimmunity
    Matthias von Herrath
    La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121 1118, USA
    Trends Immunol 24:540-5. 2003
    ..g. autoimmunity). Conversely, regulatory cells and cytokines operative at low homeostatic levels should unfold therapeutic capacities by further embellishment but not additional reduction...
  7. ncbi request reprint Microorganisms and autoimmunity: making the barren field fertile?
    Matthias G Von Herrath
    Division of Developmental Immunology, Immune Regulation Laboratory, La Jolla Institute for Allergy and Immunology, 10355 Science Centre Drive, San Diego, California 92121, USA
    Nat Rev Microbiol 1:151-7. 2003
    ....
  8. ncbi request reprint Type 1 diabetes as a relapsing-remitting disease?
    Matthias von Herrath
    La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, California 92037, USA
    Nat Rev Immunol 7:988-94. 2007
    ..Here, we propose that the immunological process that is at the root of T1D is relapsing-remitting in nature and discuss the unresolved controversies and therapeutic implications of this hypothesis...
  9. ncbi request reprint New trends in immunosuppression--sixth international congress. New drug candidates. 5-8 February 2004, Salzburg, Austria
    Matthias von Herrath
    Department of Neuropharmacology, Division of Virology IMM6, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    IDrugs 7:211-4. 2004
  10. doi request reprint Animal models of human type 1 diabetes
    Matthias von Herrath
    Center for Type 1 Diabetes Research, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA
    Nat Immunol 10:129-32. 2009
    ..This commentary addresses the utility and limitations of these models for facilitating the 'translation' of immunology research into clinical applications...
  11. pmc Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity
    Matthias G Von Herrath
    La Jolla Institute for Allergy and Immunology, San Diego, CA 92109, USA
    J Exp Med 202:1159-62. 2005
    ....
  12. pmc How can we improve the translational landscape for a faster cure of type 1 diabetes?
    Matthias von Herrath
    La Jolla Institute for Allergy and Immunology, California 92037, USA
    J Clin Invest 119:1061-5. 2009
    ....
  13. doi request reprint Remodeling rodent models to mimic human type 1 diabetes
    Matthias von Herrath
    Center for Type 1 Diabetes Research, La Jolla Institute for Allergy and Immunology, UCSD, La Jolla, CA 92037, USA
    Eur J Immunol 39:2049-54. 2009
    ....
  14. ncbi request reprint Immunoinformatics: an overview of computational tools and techniques for understanding immune function
    Matthias von Herrath
    La Jolla Institute for Allergy and Immunology, Immune Regulation Lab, 9420 Athena Circle, La Jolla, CA 92037, USA
    Expert Rev Clin Immunol 3:993-1002. 2007
    ..This review addresses why in silico modeling is needed in immunology research, highlights some of the major areas of research and suggests what may be important for the future of immunoinformatics...
  15. ncbi request reprint E1-INT (Transition Therapeutics/Novo Nordisk)
    Matthias von Herrath
    La Jolla Institute for Allergy and Immunology, Department of Developmental Immunology, San Diego, CA 92121, USA
    Curr Opin Investig Drugs 6:1037-42. 2005
    ..The compound is currently undergoing phase II clinical trials...
  16. ncbi request reprint Islet regeneration needed for overcoming autoimmune destruction - considerations on the pathogenesis of type 1 diabetes
    Matthias von Herrath
    Immune Regulation Laboratory, La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121, USA
    Pediatr Diabetes 5:23-8. 2004
    ..The recent development of novel technologies will allow more precise quantification of in vivo destruction and regeneration in order to test these hypotheses...
  17. ncbi request reprint Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance
    Matthias G Von Herrath
    Department of Immune Regulation, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
    J Immunol 168:933-41. 2002
    ..Thus, administration of nonmitogenic CD3 prevents diabetes by sufficient systemic reduction of (auto)aggressive lymphocytes, but without compromising antiviral immune competence...
  18. ncbi request reprint SOCS-1 protects from virally-induced CD8 T cell mediated type 1 diabetes
    Ana Maria Barral
    La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    J Autoimmun 27:166-73. 2006
    ..Thus, SOCS expression renders beta-cells resistant to CTL attack in a mouse model of T1D...
  19. pmc Transforming growth factor-beta suppresses the activation of CD8+ T-cells when naive but promotes their survival and function once antigen experienced: a two-faced impact on autoimmunity
    Christophe M Filippi
    La Jolla Institute for Allergy and Immunology, La Jolla, California, USA
    Diabetes 57:2684-92. 2008
    ..We investigated the differential effect of this cytokine on CD8(+) T-cells in autoimmunity and antiviral immunity...
  20. pmc A viral epitope that mimics a self antigen can accelerate but not initiate autoimmune diabetes
    Urs Christen
    Immune Regulation Lab, Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, California 92121, USA
    J Clin Invest 114:1290-8. 2004
    ..Sequential heterologous viral infections might therefore act in concert to precipitate clinical autoimmune disease, even if single exposure to a viral mimic does not always cause sufficient tissue destruction...
  21. ncbi request reprint Islet-specific expression of CXCL10 causes spontaneous islet infiltration and accelerates diabetes development
    Antje Rhode
    Immune Regulation Laboratory, Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
    J Immunol 175:3516-24. 2005
    ..Our results indicate that CXCL10 expression accelerates the autoimmune process by enhancing the migration of Ag-specific lymphocytes to their target site...
  22. ncbi request reprint Minimal impact of a de novo-expressed beta-cell autoantigen on spontaneous diabetes development in NOD mice
    Marianne M Martinic
    Immune Regulation Lab DI 3, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA
    Diabetes 56:1059-68. 2007
    ..Thus, autoreactivity toward de novo-expressed beta-cell autoantigens will not accelerate autoimmunity unless large numbers of antigen-experienced autoreactive T-cells expressing the appropriate chemokine receptors are present...
  23. ncbi request reprint CD8alphaalpha-mediated survival and differentiation of CD8 memory T cell precursors
    Loui T Madakamutil
    La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121, USA
    Science 304:590-3. 2004
    ..Thus, memory precursors can be identified among primary effector cells and are selected for survival and differentiation by CD8alphaalpha...
  24. pmc Essential role for TLR9 in prime but not prime-boost plasmid DNA vaccination to activate dendritic cells and protect from lethal viral infection
    Diane Rottembourg
    La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    J Immunol 184:7100-7. 2010
    ..These results suggest that the TLR9 signaling pathway is involved in the efficacy of plasmid vaccination; therefore, it should remain a focus in the development or amelioration of vaccines to treat infections in humans...
  25. ncbi request reprint Virally induced inflammation triggers fratricide of Fas-ligand-expressing beta-cells
    Urs Christen
    Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, California, USA
    Diabetes 53:591-6. 2004
    ..Expression of Fas-L therefore might not be protective in situations in which viral inflammation can be expected, resulting in Fas induction on the targeted cell itself...
  26. pmc TLR2 signaling improves immunoregulation to prevent type 1 diabetes
    Christophe M Filippi
    La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    Eur J Immunol 41:1399-409. 2011
    ..We identify novel mechanisms by which TLR2 promotes immunoregulation and controls autoimmune diabetes in naïve or infected hosts. This work should help understand T1D etiology and develop novel immune-based therapeutic interventions...
  27. doi request reprint No significant CTL cross-priming by dendritic cell-derived exosomes during murine lymphocytic choriomeningitis virus infection
    Ken Coppieters
    Immune Regulation Laboratory DI 3, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    J Immunol 182:2213-20. 2009
    ..Thus, DC-derived exosomes do not appear to contribute significantly to CTL priming during acute LCMV infection...
  28. pmc Expression level of a pancreatic neo-antigen in beta cells determines degree of diabetes pathogenesis
    Marianne M Martinic
    Type 1 Diabetes Center at the La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    J Autoimmun 35:404-13. 2010
    ..Therefore, autoantigens such as insulin that are expressed at higher levels in beta cells might have a more profound impact on diabetes pathogenesis...
  29. ncbi request reprint Among CXCR3 chemokines, IFN-gamma-inducible protein of 10 kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-gamma (CXCL9) imprints a pattern for the subsequent development of autoimmune disease
    Urs Christen
    Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
    J Immunol 171:6838-45. 2003
    ....
  30. ncbi request reprint Virally induced inflammation and therapeutic avenues in type 1 diabetes
    Urs Christen
    Immune Regulation Laboratory, La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121, USA
    Endocrinol Metab Clin North Am 33:45-58, viii. 2004
  31. pmc T-bet controls autoaggressive CD8 lymphocyte responses in type 1 diabetes
    Amy E Juedes
    Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, 10355 Science Center Dr, San Diego, CA 92121, USA
    J Exp Med 199:1153-62. 2004
    ..This observation points toward a therapeutic opportunity for the treatment of T1D and other autoimmune disorders...
  32. doi request reprint NKG2D blockade facilitates diabetes prevention by antigen-specific Tregs in a virus-induced model of diabetes
    Tom L Van Belle
    Type 1 Diabetes Center of San Diego, La Jolla Institute for Allergy and Immunology, La Jolla, 9420 Athena Circle, San Diego, CA 92037, USA
    J Autoimmun 40:66-73. 2013
    ....
  33. pmc Interleukin-21 receptor-mediated signals control autoreactive T cell infiltration in pancreatic islets
    Tom L Van Belle
    Type 1 Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    Immunity 36:1060-72. 2012
    ..We conclude that IL-21R controls both antigen transport by DCs and the crucial beacon function of CD4(+) cells for autoreactive CD8(+) cells to reach the islets...
  34. pmc Resolution of a chronic viral infection after interleukin-10 receptor blockade
    Mette Ejrnaes
    Immune Regulation Lab DI3, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    J Exp Med 203:2461-72. 2006
    ..Therapeutic IL-10R blockade broke the cycle of IL-10-mediated immune suppression, preventing IL-10 priming by CD8alpha- DCs and enhancing antiviral responses and thereby resolving infection without causing immunopathology...
  35. ncbi request reprint IP-10 and type 1 diabetes: a question of time and location
    Urs Christen
    Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA, USA
    Autoimmunity 37:273-82. 2004
    ....
  36. ncbi request reprint Reduction of antiviral CD8 lymphocytes in vivo with dendritic cells expressing Fas ligand-increased survival of viral (lymphocytic choriomeningitis virus) central nervous system infection
    Tom Wolfe
    Division of Immune Regulation, La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121, USA
    J Immunol 169:4867-72. 2002
    ..In terms of safety it is encouraging that resolution of the infection, at least in the case of LCMV, is not inhibited...
  37. pmc Exacerbated pathology of viral encephalitis in mice with central nervous system-specific autoantibodies
    Renaud Burrer
    Molecular and Integrative Neurosciences Department, The Scrips Research Institute, La Jolla, CA 92037, USA
    Am J Pathol 170:557-66. 2007
    ..Our study illustrates the possibility that infections can lead to much more profound immunopathology in the presence of an otherwise latent autoimmune condition...
  38. ncbi request reprint IP-10 and type 1 diabetes: a question of time and location
    Urs Christen
    Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, 10355 Science Center Dr, San Diego, CA, USA
    Autoimmunity 37:273-82. 2004
    ....
  39. pmc Cure of prediabetic mice by viral infections involves lymphocyte recruitment along an IP-10 gradient
    Urs Christen
    Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, California 92121, USA
    J Clin Invest 113:74-84. 2004
    ..Thus, virally induced proinflammatory cytokines and chemokines can influence the ongoing autoaggressive process beneficially at the preclinical stage, if produced at the correct location, time, and levels...
  40. pmc Development of autoimmune diabetes in the absence of detectable IL-17A in a CD8-driven virally induced model
    Tom L Van Belle
    Diabetes Center of San Diego, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    J Immunol 187:2915-22. 2011
    ..We conclude that viral elimination and type 1 diabetes can occur in the absence of detectable IL-17A production, suggesting IL-17A is not essential in these settings...
  41. ncbi request reprint CD40L blockade prevents autoimmune diabetes by induction of bitypic NK/DC regulatory cells
    Dirk Homann
    Department of Neuropharmacology, Division of Virology, The Scripps Research Institute, La Jolla, CA 92037, USA
    Immunity 16:403-15. 2002
    ..Furthermore, protection of prediabetic recipients was autoantigen specific and did not result in generalized immunosuppression. The origin, function, and therapeutic potential of these bitypic NK/DC regulatory cells is discussed...
  42. ncbi request reprint Manipulating the type 1 vs type 2 balance in type 1 diabetes
    Urs Christen
    Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
    Immunol Res 30:309-25. 2004
    ..In this review we will focus on the pathogenesis of T1D in a virus-induced transgenic mouse model and discuss possibilities of how an aggressive type 1-dominated immune response can be restrained and autoimmunity be abrogated...
  43. ncbi request reprint Transgenic animal models for type 1 diabetes: linking a tetracycline-inducible promoter with a virus-inducible mouse model
    Urs Christen
    Department of Immune Regulation, IR 3, La Jolla Institute for Allergy and Immunology, San Diego, CA, USA
    Transgenic Res 11:587-95. 2002
    ....
  44. pmc Pre-existing autoimmunity determines type 1 diabetes outcome after Flt3-ligand treatment
    Tom L Van Belle
    Diabetes Center at San Diego, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA
    J Autoimmun 34:445-52. 2010
    ....
  45. pmc OX40 facilitates control of a persistent virus infection
    Tobias Boettler
    Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, California, United States of America
    PLoS Pathog 8:e1002913. 2012
    ..Consequently, OX40-deficient mice fail to control LCMV clone 13 infection over time, highlighting the importance of this signaling pathway during persistent viral infection...
  46. doi request reprint Viral infections and molecular mimicry in type 1 diabetes
    Ken T Coppieters
    Type 1 Diabetes Center, The La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    APMIS 120:941-9. 2012
    ..In this review, we will take a closer look at mechanistic evidence for a potential role of viruses in T1D, with a special focus on molecular mimicry...
  47. ncbi request reprint CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
    Edith M Janssen
    Division of Cellular Immunology and Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, California 92121, USA
    Nature 421:852-6. 2003
    ..Our results demonstrate that T-cell help is 'programmed' into CD8+ T cells during priming, conferring on these cells a hallmark of immune response memory: the capacity for functional expansion on re-encounter with antigen...
  48. pmc Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodies
    Mette Ejrnaes
    Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
    Clin Dev Immunol 13:337-47. 2006
    ..First, we review recent findings that blockade of IL-10/IL-10R interaction can resolve chronic viral infection and second, we reflect on how neutralization of the chemokine CXCL10 can abrogate virus-induced type 1 diabetes...
  49. pmc Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients
    Ken T Coppieters
    Type 1 Diabetes Center, The La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    J Exp Med 209:51-60. 2012
    ..Our observations provide the first direct proof for islet autoreactivity within human islets and underscore the heterogeneous and chronic disease course...
  50. pmc Immunoregulatory mechanisms triggered by viral infections protect from type 1 diabetes in mice
    Christophe M Filippi
    La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA
    J Clin Invest 119:1515-23. 2009
    ..Our results provide what we believe to be novel mechanistic insight into the role of viruses in T1D and should be valuable for prospective studies in humans...
  51. ncbi request reprint Apoptosis of autoreactive CD8 lymphocytes as a potential mechanism for the abrogation of type 1 diabetes by islet-specific TNF-alpha expression at a time when the autoimmune process is already ongoing
    Urs Christen
    Departments of Neuropharmacology and Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    Ann N Y Acad Sci 958:166-9. 2002
    ..Here we provide a model of how experienced autoaggressive CD8 lymphocytes are dying by apoptosis as a result of beta cell-specific TNF-alpha expression at a time when the autoimmune process is already ongoing...
  52. pmc Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance
    Maya F Kotturi
    Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    J Immunol 181:2124-33. 2008
    ..Thus, our results indicate that an intrinsic property of the epitope (MHC binding affinity) and an intrinsic property of the host (naive precursor frequency) jointly dictate the immunodominance hierarchy of CD8(+) T cell responses...
  53. ncbi request reprint Different diabetogenic potential of autoaggressive CD8+ clones associated with IFN-gamma-inducible protein 10 (CXC chemokine ligand 10) production but not cytokine expression, cytolytic activity, or homing characteristics
    Mette Ejrnaes
    Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
    J Immunol 174:2746-55. 2005
    ..Thus, secretion of IFN-gamma-inducible protein-10 by autoaggressive CD8(+) lymphocytes might determine their diabetogenic capacity by affecting recruitment of cells to the insulitic lesion...
  54. ncbi request reprint Rational development of antigen-specific therapies for type 1 diabetes
    Georgia Fousteri
    La Jolla Institute for Allergy and Immunology, Department of Developmental Immunology, La Jolla, CA, USA
    Adv Exp Med Biol 601:313-9. 2007
    ....
  55. ncbi request reprint Endogenous expression levels of autoantigens influence success or failure of DNA immunizations to prevent type 1 diabetes: addition of IL-4 increases safety
    Tom Wolfe
    Departments of Neuropharmacology and Immunology, The Scripps Research Institute, La Jolla, CA, USA
    Eur J Immunol 32:113-21. 2002
    ..Our findings will be of importance for designing safe antigen-specific interventions for human type 1 diabetes...
  56. pmc Functional redundancy of CXCR3/CXCL10 signaling in the recruitment of diabetogenic cytotoxic T lymphocytes to pancreatic islets in a virally induced autoimmune diabetes model
    Ken T Coppieters
    Type 1 Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA
    Diabetes 62:2492-9. 2013
    ..Our present data in a viral mouse model challenge the notion that specific blockade of the CXCL10/CXCR3 chemokine axis halts T1D onset and progression. ..
  57. ncbi request reprint Cure of chronic viral infection by neutralizing antibody treatment
    Mette Ejrnaes
    Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
    Autoimmun Rev 6:267-71. 2007
    ....
  58. pmc Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodies
    Mette Ejrnaes
    La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
    Clin Dev Immunol 13:67-77. 2006
    ..First, we review recent findings that blockade of IL-10/IL-10R interaction can resolve chronic viral infection and second, we reflect on how neutralization of the chemokine CXCL10 can abrogate virus-induced type 1 diabetes...
  59. ncbi request reprint Induction, acceleration or prevention of autoimmunity by molecular mimicry
    Urs Christen
    Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, 10355 Science Center Dr, San Diego, CA 92121, USA
    Mol Immunol 40:1113-20. 2004
    ..Already activated autoreactive cells might be easier re-activated and primed for effector functions by cross-reactive ligands than naive lymphocytes...
  60. pmc Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditis
    Georgia Fousteri
    Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    J Autoimmun 36:210-20. 2011
    ..Altogether, these results chart the way for novel prevention and intervention strategies for viral myocarditis...
  61. ncbi request reprint Regulation of viral and autoimmune responses
    Chrystelle Asseman
    La Jolla Institute for Allergy and Immunology, Division of Immune Regulation, 10355, Science Center Drive, San Diego, CA 92121, USA
    Novartis Found Symp 252:239-53; discussion 253-67. 2003
    ..However, we have recent evidence that virus specific CD25+ cells can be generated and are able to affect antiviral responses in vivo...
  62. ncbi request reprint Cytokines and chemokines in virus-induced autoimmunity
    Urs Christen
    The Scripts Research Institute, Division of Virology, La Jolla, California, USA
    Adv Exp Med Biol 520:203-20. 2003
  63. ncbi request reprint Islet beta-cell death - fuel to sustain autoimmunity?
    Christophe M Filippi
    La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA
    Immunity 27:183-5. 2007
    ..2007) find that secondary necrosis of beta-cells can prime the autoimmune response via uptake by and activation of antigen-presenting cells through Toll-like receptor 2...
  64. doi request reprint Novel strategies to eliminate persistent viral infections
    Marianne M Martinic
    La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA
    Trends Immunol 29:116-24. 2008
    ..We discuss how future combination therapies can be used to inhibit viral synthesis as well as strengthen the antiviral response without increasing immunopathology or the development of autoimmune disease...
  65. ncbi request reprint Initiation of autoimmunity
    Urs Christen
    Immune Regulation Laboratory, Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, California 92121, USA
    Curr Opin Immunol 16:759-67. 2004
    ....
  66. ncbi request reprint Autoantibodies exacerbate the severity of MHV-induced encephalitis
    Renaud Burrer
    The Scripps Research Institute, La Jolla, California, USA
    Adv Exp Med Biol 581:399-402. 2006
  67. ncbi request reprint Regulatory T-cells in type 1 diabetes
    Amy E Juedes
    Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA, USA
    Diabetes Metab Res Rev 20:446-51. 2004
    ..This review will concentrate on two different types of regulatory T-cells, the naturally occurring ('professional') CD4+CD25+ T-cells and antigen-induced ('adaptive') CD4+ Th2-like regulatory T-cells...
  68. ncbi request reprint Control of graft-versus-host disease by regulatory T cells: which level of antigen specificity?
    Marianne M Martinic
    Immune Regulation Lab, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    Eur J Immunol 36:2299-303. 2006
    ..Such ideal interventions will hopefully retain a diverse repertoire of pathogen-specific T cells, while maintenance of self-, foreign- and alloantigen-specific Tregs ensures life-long graft tolerance...
  69. ncbi request reprint Mucosal exposure to antigen: cause or cure of type 1 diabetes?
    Georgia Fousteri
    La Jolla Institute for Allergy and Immunology, Department of Developmental Immunology 3, 9420 Athena Circle, La Jolla, CA 92037, USA
    Curr Diab Rep 7:91-8. 2007
    ....
  70. ncbi request reprint Stopping diabetes in its tracks: autologous non-myeloablative stem cell transplantation
    Georgia Fousteri
    La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA
    Regen Med 2:845-51. 2007
    ..This clinical Phase I/II trial is relevant to fine-tuning interventive protocols and contributing to the further development of suitable combination therapies to prevent and treat Type 1 diabetes...
  71. ncbi request reprint Antigen-specific induction of regulatory T cells for type 1 diabetes therapy
    Christophe Filippi
    La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
    Int Rev Immunol 24:341-60. 2005
    ....
  72. pmc CD103 is dispensable for anti-viral immunity and autoimmunity in a mouse model of virally-induced autoimmune diabetes
    Georgia Fousteri
    Diabetes Center, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA
    J Autoimmun 32:70-7. 2009
    ..While in cases of rapid microbial (CD8)-driven T1D CD103 antibody blockade may not limit disease progression or severity, in mucosally-driven cases of T1D anti-CD103 antibody treatment may provide a new and safe therapeutic avenue...
  73. pmc Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes
    Damien Bresson
    Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA
    Mol Ther 18:307-16. 2010
    ..Our findings hold important implications to understand and predict the success of antigen-based clinical trials, where responsiveness to immunotherapy might vary from patient to patient...
  74. ncbi request reprint How viral infections affect the autoimmune process leading to type 1 diabetes
    Christophe Filippi
    La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121, USA
    Cell Immunol 233:125-32. 2005
    ....
  75. ncbi request reprint Antigen-induced regulatory T cells in autoimmunity
    Matthias G Von Herrath
    La Jolla Institute for Allergy and Immunology, Division of Immune Regulation, 10355 Science Center Drive, San Diego, California 92121, USA
    Nat Rev Immunol 3:223-32. 2003
    ..In this review, we consider the nature and function of such antigen-specific T(Reg) cells, and strategies for their therapeutic induction are discussed...
  76. doi request reprint Real-time imaging of the pancreas during development of diabetes
    Marianne M Martinic
    Immune Regulation Laboratory DI 3, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    Immunol Rev 221:200-13. 2008
    ..Understanding the cellular dynamics during T1D development is critical for the rational design of immunotherapies...
  77. doi request reprint The role of the activating receptor NKG2D in autoimmunity
    Tom L Van Belle
    Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    Mol Immunol 47:8-11. 2009
    ..In this review, we discuss the current knowledge on NKG2D and its ligands in the context of autoimmune diseases and immune-mediated diseases that inadvertently target endogenous cells and/or tissue...
  78. ncbi request reprint Infections and autoimmunity--good or bad?
    Urs Christen
    Immune Regulation Laboratory, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
    J Immunol 174:7481-6. 2005
    ..Knowledge of mechanisms that underlie either positive or negative effects of infections on autoimmunity will facilitate exploration of molecular details for prospective clinical studies in the future...
  79. ncbi request reprint Pathogenesis of type 1 diabetes: a viewpoint
    Matthias G Von Herrath
    La Jolla Institute for Allergy and Immunology, San Diego, California, USA
    Adv Exp Med Biol 552:317-21. 2004
  80. doi request reprint Type 1 diabetes: etiology, immunology, and therapeutic strategies
    Tom L Van Belle
    Center for Type 1 Diabetes Research, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA
    Physiol Rev 91:79-118. 2011
    ..In this comprehensive review, we explain the genetic, environmental, and immunological data underlying the prevention and intervention strategies to constrain T1D...
  81. pmc Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs
    Damien Bresson
    Department of Developmental Immunology 3, La Jolla Institute for Allergy and Immunology, San Diego, California 92121, USA
    J Clin Invest 116:1371-81. 2006
    ..Since Tregs act site-specifically, this strategy should also be expected to reduce the potential for systemic side effects...
  82. ncbi request reprint Progress in the development of immune-based therapies for type 1 diabetes mellitus
    Matthias von Herrath
    Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA
    BioDrugs 20:341-50. 2006
    ..There are, however, a number of concerns that should be addressed in order to improve future therapeutic strategies...
  83. doi request reprint Persistent glucose transporter expression on pancreatic beta cells from longstanding type 1 diabetic individuals
    Ken T Coppieters
    Type 1 Diabetes Center, The La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    Diabetes Metab Res Rev 27:746-54. 2011
    ..It remains questionable, however, whether these surviving cells can physiologically sense and respond to glucose stimuli...
  84. pmc Immunosuppression in islet transplantation
    Tom Van Belle
    La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA
    J Clin Invest 118:1625-8. 2008
    ..Reemergence of autoreactivity is likely the main culprit underlying long-term islet graft failure, and new strategies will need to be tested to circumvent this homeostatic expansion and recurrent autoreactivity...
  85. ncbi request reprint First-trimester human fetal pancreas transplantation for type 1 diabetes treatment: an alternative approach for achieving long-term graft survival?
    Georgia Fousteri
    La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA
    Diabetes 57:525-6. 2008
  86. ncbi request reprint Resuscitating adaptive Tregs with combination therapies?
    Damien Bresson
    Developmental Immunology 3, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    Novartis Found Symp 292:50-60; discussion 60-7, 122-9, 202-3. 2008
    ....
  87. ncbi request reprint Using regulatory APCs to induce/maintain tolerance
    Amy E Juedes
    Division of Immune Regulation, La Jolla Institute for Allergy and Immunology, San Diego, California 92121, USA
    Ann N Y Acad Sci 1005:128-37. 2003
    ....
  88. ncbi request reprint Immune responsiveness, tolerance and dsRNA: implications for traditional paradigms
    Matthias G Von Herrath
    Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121, USA
    Trends Immunol 24:289-93. 2003
    ..Accumulating evidence on the immunomodulatory roles of dsRNAs warrants a reconsideration of various models of immune homeostasis...
  89. ncbi request reprint Molecular and cellular control of T1/T2 immunity at the interface between antimicrobial defense and immune pathology
    Adrian Bot
    Department of Immunology and Cancer Research, MannKind Corporation, Valencia, California, USA
    DNA Cell Biol 23:341-50. 2004
    ..Finally, we outline implications on the earlier concept of T1/T2 dichotomy, supporting a model in which these two subsets, rather than being mutually antagonistic, together facilitate the recovery from infection...
  90. pmc Minimal effect of CD103 expression on the control of a chronic antiviral immune response
    Georgia Fousteri
    Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
    Viral Immunol 23:285-94. 2010
    ..Thus, a lack of CD103 expression does not affect functional impairment of effector T-cell responses during chronic viral infection...
  91. ncbi request reprint Preferential escape of subdominant CD8+ T cells during negative selection results in an altered antiviral T cell hierarchy
    Mark K Slifka
    Oregon Health and Science University Vaccine and Gene Therapy Institute, Beaverton, OR 97006, USA
    J Immunol 170:1231-9. 2003
    ..By allowing the escape of subdominant T cells, this process still preserves a relatively broad peripheral TCR repertoire that can actively participate in antiviral and/or autoreactive immune responses...
  92. pmc Immunomodulatory dendritic cells require autologous serum to circumvent nonspecific immunosuppressive activity in vivo
    Claus Haase
    Hagedorn Research Institute, Niels Steensens Vej 6, DK 2820 Gentofte, Denmark
    Blood 106:4225-33. 2005
    ....
  93. pmc The role of innate immunity in autoimmunity
    Jean Francois Bach
    INSERM U580, Hopital Necker, Paris, France
    J Exp Med 200:1527-31. 2004
    ....
  94. pmc Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease
    Robert S Fujinami
    Department of Neurology, University of Utah School of Medicine, 30 N 1900 E, 3R330 SOM, Salt Lake City, UT 84132 2305, USA
    Clin Microbiol Rev 19:80-94. 2006
    ..These mechanisms are discussed in the context of multiple sclerosis, myocarditis, and diabetes, three immune-medicated diseases often linked with virus infections...
  95. ncbi request reprint Interfacing dendritic and natural killer cells: a tool for targeted tolerance induction?
    Dirk Homann
    Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, CO, USA
    Transplantation 76:1657-61. 2003
  96. pmc Lack of intrinsic CTLA-4 expression has minimal effect on regulation of antiviral T-cell immunity
    Dirk Homann
    Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center Mail stop B140, P O Box 6511, Aurora, CO 80045, USA
    J Virol 80:270-80. 2006
    ..These findings have implications for the physiologic, pathological, and therapeutic regulation of costimulation...
  97. pmc Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions
    Catherine B Renard
    Department of Pathology, University of Washington, Seattle, Washington, USA
    J Clin Invest 114:659-68. 2004
    ..Thus, diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions...

Research Grants27

  1. DNA Vaccination & Regulatory Cells in Type I Diabetes
    Matthias von Herrath; Fiscal Year: 2003
    ..abstract_text> ..
  2. Role of a Non-Tolerant Autoantigen in Autoimmunity
    Matthias von Herrath; Fiscal Year: 2007
    ..abstract_text> ..
  3. Animal Models in Type 1 Diabetes and Multiple Sclerosis
    Matthias von Herrath; Fiscal Year: 2006
    ..Additionally, we expect that this symposium will be of interest to junior faculty working in the areas of autoimmune disease research, as well as patient advocacy groups. ..
  4. Achieving Therapeutic Antigent-Specific Tolerance in Type 1 Diabetes
    Matthias von Herrath; Fiscal Year: 2007
    ..These assays should provide strong guidance to the goals of the clinical project (#3, Herold). ..
  5. CXCR3 Chemokines in Type I Diabetes
    Matthias von Herrath; Fiscal Year: 2009
    ..Aim 1: Importance of IP-10 in the pathogenesis of T1D - therapeutic blockade and mechanistic analyses. Aim 2: Importance of IP-10 during islet allograft rejection - therapeutic blockade and mechanistic analyses. ..
  6. How IL-10R blockade can resolve persistent viral infections
    Matthias G Von Herrath; Fiscal Year: 2010
    ..In order to assure that our findings reach those groups working on HIV and HCV, cooperations have been established with leading groups in the field. ..
  7. Role of a Non-Tolerant Autoantigen in Autoimmunity
    Matthias von Herrath; Fiscal Year: 2006
    ..abstract_text> ..
  8. Role of a Non-Tolerant Autoantigen in Autoimmunity
    Matthias von Herrath; Fiscal Year: 2003
    ..We believe that these two goals will greatly improve our understanding of how autoantigens are driving an autoaggressive process and during which phases of the diabetogenic response the initiating antigen(s) are important. ..
  9. IMMUNE TOLERANCE INDUCTION BY APOPTOTIC BODIES
    Matthias von Herrath; Fiscal Year: 2005
    ..abstract_text> ..
  10. How Does blockade of CD40/CD40L Prevent Autoimmunity?
    Matthias von Herrath; Fiscal Year: 2005
    ..Therefore, the direct comparison of three autoimmune models will enable us to define, which in vivo consequences of costimulation blockade occur more commonly and which are restricted to a given experimental situation. ..
  11. DNA Vaccination & Regulatory Cells in Type I Diabetes
    Matthias von Herrath; Fiscal Year: 2006
    ..abstract_text> ..
  12. How IL-10R blockade can resolve persistent viral infections
    Matthias von Herrath; Fiscal Year: 2009
    ..In order to assure that our findings reach those groups working on HIV and HCV, cooperations have been established with leading groups in the field. ..